- HPV vaccination -- it's working well. Lo, Min Karen // New Zealand Doctor;11/16/2011, p26
The article reports on the reduction of human papillomavirus (HPV) cases worldwide, following the development of the first HPV vaccines in Australia. It offers information on the success of clinical trials on Cervarix and Gardasil, including the promotion of DNA testing in Mexico. It examines...
- Pharma: Clinic Roundup. // BioWorld Today;10/3/2012, Vol. 23 Issue 192, p9
This section offers news briefs on the pharmaceutical sector including the positive results obtained by Bristol-Myers Squibb and Pfizer from its Eliquis trial, data reported by Janssen Research & Development LCC from its canagliflozin study, and the study conducted by Merck & Co. on a human...
- Vaccibody Targeting HPV Infection via DNA Vaccine. Sheridan, Cormac // BioWorld International;11/14/2012, Vol. 17 Issue 46, p3
This article reports on the two million euros contract received by Vaccibody AS from the Norwegian Research Council to develop an effective therapeutic vaccine against human papillomavirus (HPV) infection. The contract will allow the company to take its first DNA-based vaccine, VB10.16, to...
- A long story made too short: surrogate variables and the communication of HPV vaccine trial results. Gerhardus, Ansgar; Razum, Oliver // Journal of Epidemiology & Community Health;May2010, Vol. 64 Issue 5, p1
The article considers the use of surrogate variables in clinical trials and the communication of human papillomavirus (HPV) vaccine trial findings. The author looks at the association between epidemiologists and surragate variables. The author believes that introducing surrogate variables...
- Raising Expectations For Subunit Vaccine. Schiller, John T.; Lowy, Douglas R. // Journal of Infectious Diseases;May2015, Vol. 211 Issue 9, p1373
Multidose regimens are recommended for all prophylactic subunit vaccines. Recent findings from clinical trials of an human papillomavirus virus-like particle vaccine suggest that it may be possible to develop effective single-dose subunit vaccines. The broad implications of these findings are...
- Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. Laprise, Jean-François; Markowitz, Lauri E.; Chesson, Harrell W.; Drolet, Mélanie; Brisson, Marc // Journal of Infectious Diseases;9/1/2016, Vol. 214 Issue 5, p685
A recent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 and 3 doses may have comparable vaccine efficacy. We used an individual-based transmission-dynamic model...
- Device takes CASP testing to heart. // Engineer (00137758);2/28/2011, Vol. 296 Issue 7812, p7
The article reports on the launching of the wrist-mounted device used to monitor blood-pressure developed at Leicester University.
- UNDER PRESSURE. Laposky, John // TWICE: This Week in Consumer Electronics;7/5/2011, Vol. 26 Issue 14, p34
The article reports that the functionalities and features of iHealth's BP3 Blood Pressure Monitoring System can be accessed at the Website,www.twice.com/twicejuly5.
- The mercury sphygmomanometer: End of an era? Lawrence, Leah // Endocrine Today;Mar2011, Vol. 9 Issue 3, p59
The article offers information on the mercury sphygmomanometer, which was invented in 1901 for taking blood pressure measurements.